This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Christensen, J. G. Articles by Elliott, W. L. Search for Related Content PubMed PubMed Citation Articles by Christensen, J. G. Articles by Elliott, W. L.

¹ Pfizer Global Research and Development, La Jolla Labs, La Jolla, California; ² Pfizer Global Research and Development, Groton Labs, Groton, Connecticut; ³ Formerly Department of Cancer Research, ⁴ Pfizer Global Research and Development, Ann Arbor Laboratories; and ⁵ Molecular Imaging Research, Inc., Ann Arbor, Michigan

Requests for reprints: James G. Christensen, Pfizer Global Research and Development, La Jolla Labs, 10724 Science Center Drive, La Jolla, CA 92121. Phone: 858-638-6336; Fax: 858-526-4120. E-mail: james.christensen{at}pfizer.com

CI-1033 (N-[4-[N-(3-chloro-4-fluorophenyl)amino-7-[3-(4-morpholynyl)propoxy]quinazolin-6-yl]acrylamide, PD 0183805-mesylate salt) was identified as a potent, selective inhibitor of erbB family tyrosine kinases, which are overexpressed in a number of solid tumors and have been shown to be involved in tumor progression. Because objective response of clinical patients to erbB-targeted therapies like CI-1033 has been observed only in a subset of cancer patients that exhibit the intended molecular targets, much emphasis has been placed on the identification of biomarkers of antitumor efficacy. Vascular endothelial growth factor (VEGF) and interleukin-8 (IL-8) were considered as potential biomarkers for CI-1033 due to ease of detection in patient plasma and showed roles in angiogenesis and cancer progression and positive regulation by the erbB receptor family. In the present studies, mice bearing established xenografts (A431 epidermoid carcinoma, H125 non–small cell lung carcinoma, SF767 glioblastoma, and MDA-MB-468 mammary carcinoma) were treated with efficacious and subefficacious doses of CI-1033, and plasma levels and xenograft gene expression of VEGF and IL-8 were evaluated. Oral administration of CI-1033 to tumor-bearing mice at efficacious doses resulted in markedly decreased levels of VEGF and/or IL-8 plasma levels and tumor mRNA levels relative to vehicle-treated control mice in xenograft models that exhibited evaluable levels of these markers. In contrast, subefficacious doses of CI-1033 did not significantly affect VEGF or IL-8 levels in any of the xenograft models. These studies indicate that plasma VEGF and IL-8 may have use as biomarkers of antitumor efficacy for epidermal growth factor receptor/erbB–targeted therapies such as CI-1033 and suggest that further clinical study of these markers in cancer patients are warranted.

Received 8/17/04; revised 3/ 2/05; accepted 3/29/05.

This article has been cited by other articles:

				R. G. Zinner, J. Nemunaitis, I. Eiseman, H. J. C. Shin, S. C. Olson, J. Christensen, X. Huang, P. F. Lenehan, N. J. Donato, and D. M. Shin Phase I Clinical and Pharmacodynamic Evaluation of Oral CI-1033 in Patients with Refractory Cancer Clin. Cancer Res., May 15, 2007; 13(10): 3006 - 3014. [Abstract] [Full Text] [PDF]